Goldman Sachs’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-12,238
| Closed | -$10.1K | – | 6269 |
|
|
2025
Q1 | $10.1K | Sell |
12,238
-5,805
| -32% | -$5.59K | ﹤0.01% | 5969 |
|
|
2024
Q4 | $17.1K | Sell |
18,043
-3,647
| -17% | -$3.44K | ﹤0.01% | 5915 |
|
|
2024
Q3 | $21.7K | Buy |
21,690
+3,905
| +22% | +$4.32K | ﹤0.01% | 5668 |
|
|
2024
Q2 | $22.1K | Sell |
17,785
-110
| -0.6% | -$112 | ﹤0.01% | 5510 |
|
|
2024
Q1 | $23.3K | Sell |
17,895
-1,748
| -9% | -$1.99K | ﹤0.01% | 5384 |
|
|
2023
Q4 | $24.6K | Sell |
19,643
-7,769
| -28% | -$8.6K | ﹤0.01% | 5434 |
|
|
2023
Q3 | $35.6K | Sell |
27,412
-7,413
| -21% | -$12K | ﹤0.01% | 5310 |
|
|
2023
Q2 | $59.9K | Sell |
34,825
-162,145
| -82% | -$257K | ﹤0.01% | 5443 |
|
|
2023
Q1 | $288K | Sell |
196,970
-4,454
| -2% | -$8.54K | ﹤0.01% | 5131 |
|
|
2022
Q4 | $326K | Sell |
201,424
-68,361
| -25% | -$157K | ﹤0.01% | 5100 |
|
|
2022
Q3 | $904K | Sell |
269,785
-147,457
| -35% | -$666K | ﹤0.01% | 4586 |
|
|
2022
Q2 | $1.52M | Buy |
417,242
+207,417
| +99% | +$940K | ﹤0.01% | 4290 |
|
|
2022
Q1 | $1.52M | Buy |
209,825
+43,265
| +26% | +$369K | ﹤0.01% | 4473 |
|
|
2021
Q4 | $2.26M | Buy |
166,560
+50,071
| +43% | +$783K | ﹤0.01% | 4154 |
|
|
2021
Q3 | $2.44M | Buy |
116,489
+88,325
| +314% | +$1.9M | ﹤0.01% | 4001 |
|
|
2021
Q2 | $674K | Buy |
28,164
+9,684
| +52% | +$245K | ﹤0.01% | 5033 |
|
|
2021
Q1 | $541K | Sell |
18,480
-24,051
| -57% | -$705K | ﹤0.01% | 5059 |
|
|
2020
Q4 | $1.27M | Buy |
+42,531
| New | +$1.33M | ﹤0.01% | 4044 |
|
Goldman Sachs's KRON Position: Q2 2025 in Review
Goldman Sachs sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 12,238 shares — an estimated $10.1K sold.
Goldman Sachs first reported a position in KRON in Q4 2020 and held it in 18 quarters. The position peaked at $2.44M in Q3 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Goldman Sachs reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Goldman Sachs sold 12,238 Kronos Bio shares in Q2 2025, an estimated $10.1K.
- Goldman Sachs first reported a position in Kronos Bio in Q4 2020 and held it in 18 quarters.
- Goldman Sachs's Kronos Bio position peaked at $2.44M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Goldman Sachs's 13F filing for Q2 2025, filed 14 Aug 2025.